Tag:
Joe Jimenez
Latest Headlines
Latest Headlines
Novartis CEO eyes growth strategies for Alcon
Novartis ( $NVS ) CEO Joe Jimenez ( photo ) told Reuters in an interview about his plans for the company's new eye-care division Alcon, which include broader use of implanted lenses and a larger presence
Jimenez aims to keep off-patent Diovan in blockbuster territory
Yesterday, we got some hints about Pfizer's post-patent strategy for Lipitor. Novartis ( $NVS ) CEO Joe Jimenez ( photo ) is also thinking patents. He's now talking about his company's post-patent plans
Novartis' interest in buying Gen-Probe fizzles, WSJ reports
Novartis' appetite for deals is expected to grow in the near future, but the Swiss drug giant ($NVS) may no longer be interested in gobbling up diagnostic test provider Gen-Probe. After speculation
Novartis Q2 shines on new meds, cost cuts
Novartis ( $NVS ) kicked off Big Pharma's earnings release with a nice surge in profits. Sales grew by 27% to $14.9 billion, including an 8% increase at the pharma unit. Profits rose by 12%. The strong
Novartis' desire for deals to return soon, CEO says
Novartis ( $NVS ) could soon be back on the acquisition trail. CEO Joe Jimenez ( photo ) told Swiss newspaper Aargauer Zeitung that the company's first priority is paying down $22 billion in debt, but
Will Novartis follow through with Gen-Probe bid?
Novartis CEO Joe Jimenez ( photo ) said last week that one prime dealmaking area for his company might be diagnostics. Along with potential buys in animal health, generics, biotech and consumer health,
Novartis scouts bolt-on deals of up to $3B
Novartis is scouting around for bolt-on deals. CEO Joe Jimenez ( photo ) says the Swiss company would spend up to $3 billion on consumer health and veterinary medicine acquisitions to beef up its
Novartis dismisses senior staffers for misconduct
When CEO Joe Jimenez ( photo ) went on an international tour of Novartis facilities, he ran across some behavior he didn't like. So, the company has fired several managers for ethical misconduct--and
Novartis CEO outlines a winning drug development strategy
Novartis ( $NVS ) CEO Joe Jimenez took a minute during a recent interview with Fortune to explain the company's drug development strategy. Rather than go after a blockbuster indication, Novartis
Novartis chief continues cost-cutting drive
Novartis ( $NVS ) chief Joe Jimenez ( photo ) started slashing expenses at the drugmaker even before he took over the CEO's job. That cost-cutting has continued apace, with jobs and facilities facing the
